A L Kung
Overview
Explore the profile of A L Kung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1871
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shukla N, Levine M, Gundem G, Domenico D, Spitzer B, Bouvier N, et al.
Nat Commun
. 2022 May;
13(1):2485.
PMID: 35585047
The utility of cancer whole genome and transcriptome sequencing (cWGTS) in oncology is increasingly recognized. However, implementation of cWGTS is challenged by the need to deliver results within clinically relevant...
2.
Oberg J, Sireci A, Mansukhani M, Nagy P, Glade Bender J, Kung A
Value Health
. 2016 May;
17(7):A645.
PMID: 27202319
No abstract available.
3.
Etchin J, Montero J, Berezovskaya A, Le B, Kentsis A, Christie A, et al.
Leukemia
. 2015 Jul;
30(1):190-9.
PMID: 26202935
Currently available combination chemotherapy for acute myeloid leukemia (AML) often fails to result in long-term remissions, emphasizing the need for novel therapeutic strategies. We reasoned that targeted inhibition of a...
4.
Tai Y, Landesman Y, Acharya C, Calle Y, Zhong M, Cea M, et al.
Leukemia
. 2013 Apr;
28(1):155-65.
PMID: 23588715
The key nuclear export protein CRM1/XPO1 may represent a promising novel therapeutic target in human multiple myeloma (MM). Here we showed that chromosome region maintenance 1 (CRM1) is highly expressed...
5.
Krivtsov A, Figueroa M, Sinha A, Stubbs M, Feng Z, Valk P, et al.
Leukemia
. 2012 Dec;
27(4):852-60.
PMID: 23235717
Mixed lineage leukemia (MLL)-fusion proteins can induce acute myeloid leukemias (AMLs) from either hematopoietic stem cells (HSCs) or granulocyte-macrophage progenitors (GMPs), but it remains unclear whether the cell of origin...
6.
Etchin J, Sun Q, Kentsis A, Farmer A, Zhang Z, Sanda T, et al.
Leukemia
. 2012 Aug;
27(1):66-74.
PMID: 22847027
Drugs that target the chief mediator of nuclear export, chromosome region maintenance 1 protein (CRM1) have potential as therapeutics for leukemia, but existing CRM1 inhibitors show variable potencies and a...
7.
Weisberg E, Liu Q, Nelson E, Kung A, Christie A, Bronson R, et al.
Leukemia
. 2012 Apr;
26(10):2233-44.
PMID: 22469781
Acute myeloid leukemia (AML) progenitors are frequently characterized by activating mutations in the receptor tyrosine kinase Fms-like tyrosine kinase-3 (FLT3). Protein tyrosine kinases are integral components of signaling cascades that...
8.
Weisberg E, Azab A, Manley P, Kung A, Christie A, Bronson R, et al.
Leukemia
. 2011 Dec;
26(5):985-90.
PMID: 22182920
Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow microenvironment of chronic...
9.
Reddy M, Fernandes M, Deshpande A, Weisberg E, Inguilizian H, Abdel-Wahab O, et al.
Leukemia
. 2011 Aug;
26(3):481-9.
PMID: 21860432
Myeloproliferative neoplasms are characterized by overproduction of myeloid lineage cells with frequent acquisition of oncogenic JAK2V617F kinase mutations. The molecular mechanisms that regulate energy requirements in these diseases are poorly...
10.
Weisberg E, Ray A, Barrett R, Nelson E, Christie A, Porter D, et al.
Leukemia
. 2010 Sep;
24(12):2100-9.
PMID: 20844561
Drug resistance is a growing concern with clinical use of tyrosine kinase inhibitors. Utilizing in vitro models of intrinsic drug resistance and stromal-mediated chemoresistance, as well as functional mouse models...